Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA970A + CV8102 in HCC
NCT03203005Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of IMA970A in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and T-cell response in peripheral blood. Started Sep 2017; status: completed.
02
Drugs
IMA970A
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03203005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203005.